Drug Trial Radar · NCT00117767
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Last checked: Nov 19, 2026Latest source record: May 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
720
Actual
Start
Jun 2004
Primary completion
Mar 2006
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
Conditions
- Tinea Capitis
Interventions
Terbinafine hydrochloride (HCl)Drug
Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
GriseofulvinDrug
Griseofulvin pediatric suspension o.d. administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete cure (negative mycology and clinical cure) rate at Week 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Pharmaceuticals
East Hanover, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.